Medical Policy

Effective Date:01/01/2021 Title:Zepzelca (lurbinectedin)
Revision Date: Document:BI681:00
CPT Code(s):J9223
Public Statement

Effective Date:

a)    This policy will apply to all services performed on or after the above revision date which will become the new effective date.

b)    For all services referred to in this policy that were performed before the revision date, contact customer service for the rules that would apply.

1)    Zepzelca (lurbinectedin) requires prior authorization.

2)    Zepzelca is used to treat lung cancer.

3)    Zepzelca is a specialty medication covered under the medical benefit.

Medical Statement

Zepzelca (lurbinectedin) is considered medically necessary for members meeting the following criteria:

 

Small Cell Lung Cancer (must meet all)

 

1)    Diagnosis of advanced or metastatic small cell lung cancer (SCLC);

2)    Prescribed by or in consultation with an oncologist;

3)    Age > 18 years;

4)    Failure of a platinum-containing regimen (e.g. cisplatin, carboplatin), unless clinically significant adverse effects are experienced or all are contraindicated;

5)    Dose does not exceed 3.2mg/m2 every 21 days.

Approval Duration: 6 months

 

Reauthorization (12 months) is approved if member responding positively to therapy and dosing does not exceed 3.2mg/m2 every 21 days.

 

Codes Used In This BI:

 

1)    J9223       Injection, lurbinectedin, 0.1 mg

Limits
Intentially left empty
Reference

1)    Zepzelca Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; June 2020.

2)    NCCN Drugs and Biologics Compendium. Accessed online November 25, 2020.

Addendum:

1)    Effective 01-01-2021: New code J9223

Application to Products
This policy applies to all health plans administered by QualChoice, both those insured by QualChoice and those that are self-funded by the sponsoring employer, unless there is indication in this policy otherwise or a stated exclusion in your medical plan booklet. Consult the individual plan sponsor Summary Plan Description (SPD) for self-insured plans or the specific Evidence of Coverage (EOC) for those plans insured by QualChoice. In the event of a discrepancy between this policy and a self-insured customer’s SPD or the specific QualChoice EOC, the SPD or EOC, as applicable, will prevail. State and federal mandates will be followed as they apply.

Changes: QualChoice reserves the right to alter, amend, change or supplement benefit interpretations as needed.